Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status

Head & Neck ◽  
2019 ◽  
Author(s):  
Casey Means ◽  
Daniel R. Clayburgh ◽  
Lauren Maloney ◽  
David Sauer ◽  
Matthew H. Taylor ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf Mutation ◽  
Papillary Thyroid ◽  
Immune Microenvironment ◽  
Mutation Status ◽  
Tumor Immune Microenvironment

scholarly journals Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma

2020 ◽  
Vol 21 (24) ◽  
pp. 9498
Author(s):  
Sandeep Kumar Parvathareddy ◽  
Abdul K. Siraj ◽  
Padmanaban Annaiyappanaidu ◽  
Saif S. Al-Sobhi ◽  
Fouad Al-Dayel ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf Mutation ◽  
Middle Eastern ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Papillary Thyroid ◽  
Mutation Status ◽  
Cox 2 ◽  
Braf Mutant

The cyclooxygenase-2 (COX-2)–prostaglandin E2 (PGE2) pathway has been implicated in carcinogenesis, with BRAF mutation shown to promote PGE2 synthesis. This study was conducted to evaluate COX-2 expression in a large cohort of Middle Eastern papillary thyroid carcinoma (PTC), and further evaluate the prognostic significance of COX-2 expression in strata of BRAF mutation status. BRAF mutation analysis was performed using Sanger sequencing, and COX-2 expression was evaluated immunohistochemically using tissue microarray (TMA). COX-2 overexpression, noted in 43.2% (567/1314) of cases, was significantly associated with poor prognostic markers such as extra-thyroidal extension, lymph-node metastasis, and higher tumor stage. COX-2 was also an independent predictor of poor disease-free survival (DFS). Most notably, the association of COX-2 expression with DFS differed by BRAF mutation status. COX-2 overexpression was associated with poor DFS in BRAF-mutant but not BRAF wild-type PTCs, with a multivariate-adjusted hazard ratio of 2.10 (95% CI = 1.52–2.92; p < 0.0001) for COX-2 overexpressed tumors in BRAF-mutant PTC. In conclusion, the current study shows that COX-2 plays a key role in prognosis of PTC patients, especially in BRAF-mutated tumors. Our data suggest the potential therapeutic role of COX-2 inhibition in patients with BRAF-mutated PTC.

scholarly journals Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma

2015 ◽  
Vol 23 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Seo Ki Kim ◽  
Jung-Woo Woo ◽  
Jun Ho Lee ◽  
Inhye Park ◽  
Jun-Ho Choe ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Clinical Significance ◽  
Braf Mutation ◽  
Independent Predictor ◽  
Chronic Lymphocytic Thyroiditis ◽  
Papillary Thyroid ◽  
Mutation Status ◽  
Lymphocytic Thyroiditis ◽  
Low Prevalence

It has been reported that papillary thyroid carcinoma (PTC) with chronic lymphocytic thyroiditis (CLT) is less associated with extrathyroidal extension (ETE), advanced tumor stage and lymph node (LN) metastasis. Other studies have suggested that concurrent CLT could antagonize PTC progression, even in BRAF-positive patients. Since the clinical significance of the BRAF mutation has been particularly associated with conventional PTC, the purpose of this study was to determine the clinical significance of CLT according to BRAF mutation status in conventional PTC patients. We retrospectively reviewed the medical records of 3332 conventional PTC patients who underwent total thyroidectomy with bilateral central neck dissection at the Thyroid Cancer Center of Samsung Medical Center between January 2008 and June 2015. In this study, the prevalence of BRAF mutation was significantly less frequent in conventional PTC patients with CLT (76.9% vs 86.6%). CLT was an independent predictor for low prevalence of ETE in both BRAF-negative (OR=0.662, P=0.023) and BRAF-positive (OR=0.817, P=0.027) conventional PTC patients. In addition, CLT was an independent predictor for low prevalence of CLNM in both BRAF-negative (OR=0.675, P=0.044) and BRAF-positive (OR=0.817, P=0.030) conventional PTC patients. In conclusion, BRAF mutation was significantly less frequent in conventional PTC patients with CLT. However, CLT was an independent predictor for less aggressiveness in conventional PTC patients regardless of BRAF mutation status.

scholarly journals Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements

2007 ◽  
Vol 20 (7) ◽  
pp. 779-787 ◽  
Author(s):  
Sien-Yi Sheu ◽  
Suzan Schwertheim ◽  
Karl Worm ◽  
Florian Grabellus ◽  
Kurt Werner Schmid
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Braf Mutation ◽  
Papillary Thyroid ◽  
Diffuse Sclerosing Variant

Surgical management of papillary thyroid carcinoma according to BRAF mutation

2017 ◽  
Vol 72 ◽  
pp. S110-S111
Author(s):  
A. Polyakov ◽  
N. Volchenko ◽  
P. Nikiforovich ◽  
E. Slavnova ◽  
A. Kudryavtseva ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Surgical Management ◽  
Braf Mutation ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document